Technology New mRNA Melanoma Vaccine Cuts Recurrence Risk by over 40 Percent in 2026 Trial Breakthrough October 25, 2026 Bright Esagbodje A 2026 Phase 3 trial shows a personalized mRNA melanoma vaccine reduces recurrence risk by over 40 percent, marking a major advance in cancer immunotherapy.
